Table 1.
LEAN 1 and LEAN 2 study participant characteristics.
| Characteristic | Total (n = 149) | Intervention (n = 91) | Usual Care (n = 58) | P valuea |
|---|---|---|---|---|
| Age, years, mean (SD), range (n = 149) |
58.0 ± 7.8 32-73 |
59.0 ± 7.3 44-73 |
56.3 ± 8.4 32-72 |
0.04 |
| Postmenopausal, n (%) (n = 149) | 124 (83) | 77 (85) | 47 (81) | 0.57 |
| Race/Ethnicity, n (%) (n = 149) | 0.53 | |||
| White (non-Hispanic) | 131 (88) | 82 (90) | 49 (85) | |
| Black or African American | 10 (7) | 5 (6) | 5 (9) | |
| Hispanic | 6 (4) | 3 (3) | 3 (5) | |
| Other | 1 (1) | 0 (0) | 1 (2) | |
| Declined to report | 1 (1) | 1 (1) | 0 (0) | |
| Education, n (%) (n = 149) | 0.17 | |||
| High school degree | 19 (13) | 10 (11) | 9 (16) | |
| Some college degree | 39 (26) | 22 (24) | 17 (29) | |
| College degree | 38 (26) | 29 (32) | 9 (16) | |
| Graduate degree | 53 (36) | 30 (33) | 23 (40) | |
| Time from diagnosis to LEAN enrollment, years, mean (SD) (n = 147) | 2.9 ± 2.5 | 2.7 ± 2.0 | 3.2 ± 3.1 | 0.25 |
| Body weight, kg, mean (SD) (n = 149) | 87.8 ± 17.7 | 85.0 ± 16.9 | 92.3 ± 18.1 | 0.01 |
| Percent body fat (SD) (n = 149) | 43.2 ± 4.9 | 43.3 ± 4.5 | 42.9 ± 5.5 | 0.63 |
| Baseline BMI, kg/m2, mean (SD) (n = 149) | 33.2 ± 6.4 | 32.2 ± 6.0 | 34.6 ± 6.7 | 0.03 |
| BMI (kg/m2) (n = 149) | 0.02 | |||
| Overweight BMI < 30 | 61 (41) | 44 (48) | 17 (29) | |
| Obese BMI ≥ 30 | 88 (59) | 47 (52) | 41 (71) | |
| Disease stage, n (%) (n = 149) | 0.81 | |||
| DCIS (stage 0) | 25 (17) | 13 (14) | 12 (21) | |
| Stage I | 74 (50) | 46 (51) | 28 (48) | |
| Stage II | 36 (24) | 22 (24) | 14 (24) | |
| Stage III | 11 (7) | 8 (9) | 3 (5) | |
| Unknown | 3 (2) | 2 (2) | 1 (2) | |
| Adjuvant treatment after surgery, n (%) (n = 149) | 0.38 | |||
| None | 17 (11) | 8 (9) | 9 (16) | |
| Radiation only | 57 (38) | 34 (37) | 23 (40) | |
| Chemotherapy only | 23 (15) | 17 (19) | 6 (10) | |
| Radiation and chemotherapy | 52 (35) | 32 (35) | 20 (35) | |
| Current endocrine therapy, n (%) (n = 128) | 0.07 | |||
| Aromatase inhibitors (AI’s) only | 30 (23) | 21 (26) | 9 (19) | |
| Tamoxifen | 43 (34) | 20 (25) | 23 (48) | |
| Both | 9 (7) | 6 (8) | 3 (6) | |
| None | 46 (36) | 33 (41) | 13 (27) |
aT-tests for continuous variables and chi-squared tests or Fischer’s exact tests for categorical variables.